 |
ISMAIL KOLA, Ph.D.
Senior Vice President, Discovery Research, Schering-Plough Research Institute
Chief Scientific Officer
Schering-Plough Corporation
Kenilworth, New Jersey
Ismail Kola, Ph.D., is senior vice president, Discovery Research, Schering-Plough Research Institute, the pharmaceutical research arm of Schering-Plough Corporation, and Chief Scientific Officer, Schering Plough Corporation.
Kola is responsible for a team of 1,800 people at the company's discovery, translational and early clinical research sites in New Jersey, California, Massachusetts, Milan, Italy; Glasgow, Scotland; Oss, the Netherlands and Singapore. He is also responsible for Early Clinical Research and Experimental Medicine.
Kola came to Schering-Plough in March 2007 from Merck, where he was most recently senior vice president and site head, Basic Research, and was responsible for atherosclerosis and cardiovascular diseases, diabetes, obesity, infectious diseases, immunology and rheumatology, animal pharmacology and basic and medicinal chemistry. He also chaired Merck's Antibacterial and Antifungal Worldwide Business Strategy Team. Prior to that, he was vice president, Research, and global head, Genomics Science and Biotechnology, with Pharmacia Corporation, and served as a consultant to SmithKline Beecham Pharmaceuticals, where he was also a member of the Genomics Advisory Board.
He holds adjunct professorships of medicine at Washington University, St Louis, Mo., and Monash University Medical School, Melbourne, Australia; a foreign adjunct professorship at The Karolinska Institute, Stockholm, Sweden; and is a William Pitt Fellow at Pembroke College, Cambridge University, UK. He has had four drugs come to market under his leadership in the industry; several others are currently under review with regulatory authorities and in late-stage development. He has authored approximately 160 publications and is the recipient of many international research prizes.
Kola holds a Ph.D. in medicine from the University of Cape Town, South Africa.
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.
|
|
